Priovant Plots Path to Phase 3 as Brepocitinib Clears Mid-Stage Skin Disease Study

According to Priovant, the Phase 2 BEACON study is the first industry-sponsored placebo-controlled trial in cutaneous sarcoidosis to deliver positive data.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top